Soleno Therapeutics Inc. | Mid-cap | Healthcare
$58.45
-1.28%
| Soleno Therapeutics Stock Comparison:
Soleno Therapeutics vs VertexSoleno Therapeutics vs RegeneronSoleno Therapeutics vs MadrigalSoleno Therapeutics vs Bio-TechneSoleno Therapeutics vs Corcept TherapeuticsSoleno Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 32.7M
Gross Profit 32.0M 97.87%
Operating Income -5.4M -16.61%
Net Income -4.7M -14.42%
EPS (Diluted) $-0.09

Balance Sheet Metrics

Total Assets 318.1M
Total Liabilities 85.8M
Shareholders Equity 232.3M
Debt to Equity 0.37

Cash Flow Metrics

Operating Cash Flow -27.9M
Free Cash Flow -32.8M

Revenue & Profitability Trend

Soleno Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i78.6M25.2M15.3M21.5M23.2M
Selling, General & Administrative i105.9M13.5M9.8M10.8M8.8M
Other Operating Expenses i-----
Total Operating Expenses i184.4M38.7M25.1M32.3M31.9M
Operating Income i-184.4M-38.7M-25.1M-32.3M-31.9M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i12.1M2.6M300.0K110.0K13.0K
Interest Expense i231.0K----
Other Non-Operating Income-3.2M-2.9M742.0K1.2M7.3M
Pre-tax Income i-175.8M-39.0M-24.1M-30.9M-24.6M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-175.8M-39.0M-24.1M-30.9M-24.6M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-170.4M-33.8M-23.9M-31.5M-37.3M
EPS (Basic) i$-4.38$-2.36$-2.87$-5.81$-5.85
EPS (Diluted) i$-4.38$-2.36$-2.87$-5.81$-5.85
Basic Shares Outstanding i4017592616492132839708853180224174681
Diluted Shares Outstanding i4017592616492132839708853180224174681

Income Statement Trend

Soleno Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i87.9M169.7M14.6M21.3M49.2M
Short-term Investments i203.5M----
Accounts Receivable i-----
Inventory i-----
Other Current Assets2.5M1.7M1.0M1.1M-
Total Current Assets i293.9M171.4M15.6M22.4M50.2M
Non-Current Assets
Property, Plant & Equipment i2.8M407.0K131.0K421.0K139.0K
Goodwill i6.8M8.7M10.7M12.6M14.6M
Intangible Assets i6.8M8.7M10.7M12.6M14.6M
Long-term Investments-----
Other Non-Current Assets83.0K165.0K-40.0K-
Total Non-Current Assets i37.1M9.3M10.8M13.1M14.7M
Total Assets i331.0M180.7M26.5M35.6M65.0M
Liabilities
Current Liabilities
Accounts Payable i8.9M3.1M1.8M3.3M3.5M
Short-term Debt i526.0K273.0K155.0K282.0K139.0K
Current Portion of Long-term Debt-----
Other Current Liabilities2.7M1.6M484.0K323.0K196.0K
Total Current Liabilities i18.7M11.5M7.3M8.0M8.6M
Non-Current Liabilities
Long-term Debt i52.3M130.0K0175.0K0
Deferred Tax Liabilities i-----
Other Non-Current Liabilities14.8M11.5M8.8M9.5M10.3M
Total Non-Current Liabilities i67.1M11.7M8.8M9.8M10.8M
Total Liabilities i85.9M23.2M16.1M17.8M19.4M
Equity
Common Stock i46.0K32.0K8.0K80.0K80.0K
Retained Earnings i-452.3M-276.4M-237.4M-213.4M-182.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i245.1M157.5M10.3M17.8M45.5M
Key Metrics
Total Debt i52.8M403.0K155.0K457.0K139.0K
Working Capital i275.1M159.9M8.3M14.4M41.6M

Balance Sheet Composition

Soleno Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-175.8M-39.0M-24.1M-30.9M-24.6M
Depreciation & Amortization i2.0M2.0M2.0M2.0M2.0M
Stock-Based Compensation i100.0M5.9M2.5M3.3M1.5M
Working Capital Changes i6.7M3.6M-671.0K-640.0K1.7M
Operating Cash Flow i-63.5M-24.5M-20.7M-26.8M-14.8M
Investing Activities
Capital Expenditures i-218.0K0-13.0K-22.0K-7.0K
Acquisitions i----0
Investment Purchases i-356.5M----
Investment Sales i131.0M----
Investing Cash Flow i-225.7M0-13.0K-22.0K-7.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i49.9M----
Debt Repayment i--0-8.0K-17.0K
Financing Cash Flow i198.8M137.9M14.1M-128.0K53.7M
Free Cash Flow i-69.3M-24.9M-20.8M-27.8M-25.2M
Net Change in Cash i-90.4M113.4M-6.6M-26.9M38.9M

Cash Flow Trend

Soleno Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -13.52
Forward P/E -26.08
Price to Book 12.44
Price to Sales 96.36
PEG Ratio 0.16

Profitability Ratios

Profit Margin 0.00%
Operating Margin -16.61%
Return on Equity -69.53%
Return on Assets -36.60%

Financial Health

Current Ratio 15.13
Debt to Equity 21.97
Beta -2.75

Per Share Data

EPS (TTM) $-4.22
Book Value per Share $4.76
Revenue per Share $0.72

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
slno3.4B-13.5212.44-69.53%0.00%21.97
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Madrigal 9.9B-20.2314.14-36.30%-54.68%17.81
Bio-Techne 9.8B136.855.083.68%6.02%23.14
Corcept Therapeutics 9.3B78.7114.6021.70%18.67%1.04

Financial data is updated regularly. All figures are in the company's reporting currency.